Author: Wellens, Judith; Colombel, Jean-Frédéric; Satsangi, Jack J; Wong, Serre-Yu
Title: SARS-CoV-2 vaccination in IBD: past lessons, current evidence and future challenges Cord-id: r6i53kc1 Document date: 2021_3_15
ID: r6i53kc1
Snippet: Since the beginning of the pandemic, patients with inflammatory bowel diseases (IBD) have been considered at high-risk for infection and complications of COVID-19. However, IBD patients and patients taking immunosuppressive therapy were excluded from clinical phase III vaccine trials, complicating the assessment of effectiveness of these new vaccines. From past experience we know that adapted vaccination strategies may be appropriate in some IBD patients to optimize immunogenicity. We review cur
Document: Since the beginning of the pandemic, patients with inflammatory bowel diseases (IBD) have been considered at high-risk for infection and complications of COVID-19. However, IBD patients and patients taking immunosuppressive therapy were excluded from clinical phase III vaccine trials, complicating the assessment of effectiveness of these new vaccines. From past experience we know that adapted vaccination strategies may be appropriate in some IBD patients to optimize immunogenicity. We review current evidence on SARS-CoV-2 vaccination relevant to IBD patients, including immune responses from humoral to cellular, emerging data on new variants and off-label vaccination schemes. We also identify clinical and scientific knowledge gaps that can be translated into both large-scale population-based studies and targeted vaccine studies to describe the precise immune responses induced by SARS-CoV-2 vaccines in IBD patients. We strongly endorse the recommendation of vaccinating IBD patients to ensure maximal protection from COVID-19 both for the individual and the community.
Search related documents:
Co phrase search for related documents- acute respiratory syndrome and adenovirus vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute respiratory syndrome and adequate level: 1, 2, 3, 4, 5, 6, 7
- acute respiratory syndrome and adequate vaccination: 1, 2, 3, 4, 5, 6, 7
- acute respiratory syndrome and long term enhancement: 1
- acute respiratory syndrome and long term follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57
- acute respiratory syndrome and long term immunological memory: 1
- acute respiratory syndrome and longitudinally seroprevalence assess: 1
- acute respiratory syndrome and low persistence: 1, 2, 3, 4, 5
- acute respiratory syndrome and low response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36
- acute respiratory syndrome and low vaccination: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
Co phrase search for related documents, hyperlinks ordered by date